Sinovac Biotech Ltd
SVQ
Company Profile
Business description
Sinovac Biotech Ltd is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including, without limitation, hepatitis A, hepatitis B, hand foot and mouth disease (HFMD) caused by EV71, seasonal influenza, H5N1 and H1N1 pandemic influenza, coronavirus, pneumococcus, poliomyelitis, varicella and mumps.
Contact
No.39, Shangdi Xi Road
Haidan District
Beijing100085
CHNT: +86 1082799800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
3,261
Stocks News & Analysis
stocks
PayPal earnings: Growth slows, new CEO appointed
We expect to lower our fair value estimate of PayPal stock.
stocks
Morningstar initiates on ASX income play
This REIT may be an option for investors seeking income.
stocks
What Goodman’s upcoming earnings could reveal about data centre & AI growth
Answering key questions about Goodman & its data centre pipeline ahead of earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,149.30 | 6.90 | -0.08% |
| CAC 40 | 8,179.50 | 1.67 | -0.02% |
| DAX 40 | 24,780.79 | 16.73 | -0.07% |
| Dow JONES (US) | 49,209.79 | 197.87 | -0.40% |
| FTSE 100 | 10,314.59 | 26.97 | -0.26% |
| HKSE | 26,834.77 | 59.20 | 0.22% |
| NASDAQ | 23,195.00 | 397.11 | -1.68% |
| Nikkei 225 | 54,720.66 | 2,065.48 | 3.92% |
| NZX 50 Index | 13,421.52 | 9.08 | 0.07% |
| S&P 500 | 6,908.31 | 68.13 | -0.98% |
| S&P/ASX 200 | 8,857.10 | 9.20 | -0.10% |
| SSE Composite Index | 4,067.74 | 51.99 | 1.29% |